Valneva is preparing to reduce its workforce by as much as 15% as the French vaccine maker continues efforts to lower operating expenses.
The company, whose portfolio includes the Japanese encephalitis vaccine Ixiaro and cholera shot Dukoral, reported first-quarter 2026 revenue of just under 31 million euros ($36.2 million), down from over 49 million euros ($57.6 million) during the same period last year. Valneva partly linked the decline to the planned phaseout of its side business distributing Bavarian Nordic vaccines in certain markets.
Even excluding that business change, however, the company’s broader outlook remains challenging. Valneva announced Wednesday that it had lowered its 2026 revenue forecast from a previously expected range of 145 million to 160 million euros ($170 million to $187 million) to a revised estimate of 135 million to 150 million euros ($158 million to $175 million). The company attributed the weaker outlook to what it described as an emerging decline in demand for travel vaccines across key markets, driven by geopolitical conditions.
Valneva has also faced setbacks beyond its commercial business. The biotech is still attempting to advance approval efforts for its Lyme disease vaccine developed in partnership with Pfizer, despite the candidate failing to meet the primary endpoint in a pivotal study.
The French vaccine developer also recently withdrew its first-in-class chikungunya vaccine Ixchiq from the U.S. market after the U.S. Food and Drug Administration raised major safety concerns, including a fatal encephalitis case the agency determined was directly linked to the vaccine.
In Wednesday’s release, Chief Financial Officer Peter Bühler said the company’s first-quarter sales reflected both the steep decline in third-party products and its strategic emphasis on proprietary vaccines. Bühler also noted that Valneva was beginning to see evidence that geopolitical instability was negatively affecting travel-related demand.
He further stated that the company had continued to significantly reduce its operating cash burn and, together with additional cost-saving initiatives and a strengthened balance sheet following financing completed in April, expected to maintain a stable cash position through the anticipated regulatory review period for its Lyme disease vaccine.
As part of these efforts, Valneva unveiled what it described as an additional restructuring initiative intended to simplify global operations. The plan is expected to reduce the company’s worldwide workforce by somewhere between 10% and 15%. At the beginning of the year, Valneva employed 674 people across Canada, Austria, France, U.S., Sweden and U.K.
The latest cuts follow an announcement late last year that Valneva would shut down its preclinical R&D site in Nantes, France, affecting 30 employees. That move consolidated all French operations at the company’s Lyon facility, while research and development activities were centralized at its Vienna, Austria, site.
According to Wednesday’s announcement, the combined restructuring measures are projected to lower operating costs in 2026 by between 25% and 35%.
Valneva has announced plans to reduce approximately 15% of its workforce as part of a broader cost-cutting initiative. The decision comes as Valneva focuses on improving operational efficiency and managing financial resources more effectively in a challenging biotech market environment.
The latest move by Valneva reflects growing pressure across the pharmaceutical and biotechnology sectors, where companies are increasingly prioritizing sustainable growth and profitability. By streamlining operations, Valneva hopes to strengthen its financial stability while continuing to invest in vaccine research and development.
The biotechnology industry has experienced significant financial pressure over the past few years, leading many companies to reevaluate operational strategies and spending priorities. Rising research and development costs, inflation, and uncertain market conditions have encouraged pharmaceutical firms to implement restructuring programs aimed at preserving long-term stability.
Company executives stated that the workforce reduction initiative is part of a broader effort to optimize resources and improve efficiency across multiple business operations. Management believes that focusing on core programs and reducing unnecessary expenses will help strengthen future performance while maintaining scientific innovation.
Global Biotech Sector Facing Cost Pressures
Across the healthcare industry, several vaccine and biotechnology companies have announced similar measures in response to changing market dynamics. Investor expectations have shifted toward profitability and disciplined spending, especially after periods of rapid expansion during recent years.
Future Outlook for Valneva
While workforce reductions are challenging, Valneva continues to position itself for long-term growth. The company aims to optimize operations, strengthen investor confidence, and maintain momentum in vaccine development initiatives.
